Initially identified from an ultrahigh throughput drug screen [18], C5-substituted 2,4-DAQs activate SMN2 promoter activity and also increase SMN localization to subnuclear gems in SMA patient fibroblasts [19]. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.